At the closing plenary session of WCLC, Paul A. Bunn, Jr, MD, presented a treatment algorithm for lung cancer and discussed where lung cancer research in North America is heading.
A previous analysis of the phase 2 BIRCH study showed that atezolizumab, a PD-L1 inhibitor, provides clinically meaningful and durable benefit as a first- and second-line therapy.
Exon 20 mutations account for 4% to 10% of EGFR mutations in NSCLC and are refractory to EGFR TKIs; there are no targeted therapies available for this patient population.
For this phase 2 study, researchers enrolled 39 patients with oligometastatic NSCLC to start pembrolizumab 200 mg every 3 weeks within 4 to 12 weeks of undergoing LAT.
ctDNA next generation sequencing of patient blood samples detected oncogenic drivers in 27 (36%) patients, including HER2 exon 20 insYVMA, BRAF L597Q, and MET exon14 mutations.
During a plenary presentation at the 18th annual WCLC, researchers presented patient-reported outcomes, including health-related QoL, disease symptoms, and physical function, from the phase 3 PACIFIC trial.
Researchers randomly assigned 56 treatment-naive patients with advanced NSCLC to 3 cohorts: nivolumab plus gemcitabine and cisplatin, nivolumab plus pemetrexed and cisplatin, and nivolumab plus paclitaxel and carboplatin.
For this cross-sectional study, researchers collected the data of 1030 adult patients with advanced NSCLC from medical chart reviews and various patient questionnaires.
One-hundred and eight patients received cisplatin plus docetaxel in the control arm; 392 patients in the experimental arm received varying treatments according to BRCA1 mRNA expression levels.
Researchers evaluated survival and socioeconomic data from 1,150,722 patients with NSCLC to determine particular factors that may predict OS.
Researchers administered savolitinib 600 mg plus gefitinib 250 mg to 44 patients, of whom 6 were T790M-positive and 5 were T790M-negative.
Investigators randomly assigned 95 patients with ED-SCLC to receive pazopanib 800 mg daily or placebo.
Initial analysis of cohort G of KEYNOTE-021 at a median of 10.6 months showed that pembrolizumab significantly improved overall response rate and progression-free survival compared with pemetrexed/carboplatin alone.
Researchers analyzed the resistance biopsies and plasma specimens of 119 patients with T790M-positive NSCLC treated with osimertinib.
Researchers enrolled 248 patients who progressed on pemetrexed-based chemotherapy with or without bevacizumab to receive second-line anetumab ravtansine or vinorelbine.
Patients diagnosed with NSCLC between 2010 and 2013 had a median OS of 14.8 months compared with 12.4 months among patients diagnosed between 2004 and 2009.
Researchers randomly assigned 89 patients with NSCLC to the SLND arm, in which patients underwent standard lung resection with SLND, or to the BML arm, in which patients received SLND plus contralateral mediastinal lymphadenectomy.
Researchers analyzed the outcomes of 7060 patients with SCLC from the SEER database to determine the rates of new CEs among patients treated with chemotherapy plus RT or chemotherapy alone.
The purpose of this study was to compare the effectiveness of SABR with CRT in prolonging time to local failure in this patient population.
A previous study noted a $30 median 30-day TKI supply copayment for privately insured patients. The median out-of-pocket cost was $452 for the same supply among patients included in this study.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Long-term Survival From Ipilimumab/Nivolumab Combination in Metastatic Melanoma
- Radiation Therapy Increases 5-year Rate of Cardiac Events in Small-cell Lung Cancer
- Questions Remain for First-line Treatment Selection and Sequencing in Advanced Melanoma
- Pazopanib: Where Does It Stand as Adjuvant Therapy in Localized RCC?
- Repeat T790M Testing Recommended for TKI-resistant Patients With NSCLC
- Lung Cancer Treatment in North America: Recent Advances and Future Promises
- Atezolizumab Maintains Clinical Benefit After 2 Years in Advanced NSCLC
- Luminespib May Be Effective in NSCLC With EGFR Exon 20 Insertion Mutation
- Pembrolizumab After Locally Ablative Therapy May Be Beneficial in Metastatic NSCLC
- Liquid Biopsies Detect Unknown Driver Mutations in Advanced NSCLC